Boehringer Struggles to Sway Court in Fight Over Drug Price Cuts

Boehringer Ingelheim struggled to convince a three-judge panel Thursday that the US government’s drug price negotiation plan violates the US Constitution and forces companies to participate in the Biden-era program.

The manufacturer told the US Court of Appeals for the Second Circuit that a lower court was wrong to reject its challenge against an Inflation Reduction Act plan established under former President Joe Biden. The Medicare Drug Price Negotiation Program gives the US powerful authority to negotiate with the pharmaceutical industry over the costs for some of the most widely used and expensive medicines covered by Medicare.

The industry has ...